Project Grant R01AI197622
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $573K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $825,050 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate glycosylated RNA (glycoRNA) control of immune homeostasis. The funded research tests the hypothesis that glycosylation of mammalian small RNAs prevents immune sensing of glycoRNAs by shielding them from endosomal toll-like receptor (TLR) sensing machinery. The work proceeds...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $523,037 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of unanchored ubiquitin chains in non-canonical inflammasome signaling. The research examines how ubiquitin regulatory X domain-containing protein 1 (UBXN1) regulates caspase-4/11-mediated inflammasome activation in response to bacterial endotoxin and...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $460,625 on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the maturation and maintenance of the germinal center niche, specifically follicular dendritic cells (FDCs). The research determines FDC longevity and turnover in young and aged mice at steady state, post-immunization, and under chronic lupus inflammatory conditions,...
- The National Institute of Allergy and Infectious Diseases awarded $624,375 to the University of Connecticut Health Center on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of MIT family transcription factors in regulating antibacterial interferon defense. The research examines how transcription factors TFE3 and TFEB direct Type I interferon responses against bacterial pathogens, particularly enterohemorrhagic Escherichia coli...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $818,300 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop modular degradation systems for extracellular proteins (MODES) as potential therapeutics for antibody-driven autoimmune disorders and heart failure. The research focuses on creating bifunctional small molecules designed to selectively remove disease-causing antibodies from circulation while preserving...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $100,228 on November 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). MIT will conduct research examining the molecular basis of T cell allorecognition in graft-versus-host disease and graft-versus-leukemia. The research uses a repertoire-scale examination to determine the molecular mechanisms underlying T cell recognition of non-self major...